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Gordon Brown’s agenda for the NHS
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The government has willed the ends, but will it provide the means and
mechanisms for effective prevention and improved outcomes?
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Gordon Brown’s first major speech on the National
Health Service was spun to the media as a populist
plea for health checks and screening programmes
to be made widely available. In reality, it offered a
reflective and wide ranging assessment of the state
of the NHS in England in its 60th year and a broad
indication of the future direction of reform.1 2 In the
process, the speech gave the clearest indication yet of
the prime minister’s agenda for health policy.
At the heart of this agenda is the need for the benefits of medical advances to be made available in the
NHS. In words that echoed Harold Wilson’s advocacy of the white heat of technology in the 1960s,
Brown praised the progress already made through
developments in clinical research, and welcomed
the establishment of Europe’s largest medical science
centre in London. He also indicated his willingness
to accept increased concentration of services and
hospital closures where there was evidence that this
would deliver improved outcomes, even if this risked
unpopularity with the public.
The speech emphasised the importance of the prevention of illness as well as the treatment of sickness.
Prevention will be promoted by offering easier access
to health checks and the provision of screening services recommended by the UK National Screening
Committee. Primary care will be expected to play
its part, with patients accessing routine tests such as
blood tests, electrocardiography, and ultrasound in
general practitioners’ surgeries. Alongside these NHS
measures, Brown called for promotion of exercise in
schools, a single labelling system to describe clearly
the nutritional value of food products, and a more
active role by employers in improving health in the
workplace.
The prime minister signalled a renewed commitment to improve the care of people with chronic diseases. Specifically, the NHS will be expected to do
more to support people to manage their own conditions through a major expansion of the lay led Expert
Patient Programme3 and, more radically, by extending to health care the use of the direct payments—personal health budgets—announced last month for older
and disabled people to buy personal (mainly social)
care.4
The speech also underlined the need to match
increased rights for patients with clearer responsibilities. In an adaptation of John F Kennedy’s aphorism,
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the prime minister argued that patients should ask of
the NHS “not just . . . what it can do for you but what,
empowered with new advice, support and information, you can do for yourself and your family.” More
detail will be available later in the year when the
much trailed NHS constitution is published, which
will set out the “NHS offer” to the public and clarify
how the government expects people to take responsibility for managing their own health.
Another key theme was the government’s commitment to improve access to primary care services.
As well as the familiar refrain that practices should
extend opening hours in the evenings and weekends,
the prime minister indicated that NHS foundation
trusts would be allowed to provide primary care in
future. This opened up the prospect of increased competition in primary care, both from the independent
sector and from other parts of the NHS—Brown’s
speech indicated that there would be no “no go” areas
of reform as further progress is made in extending
patient choice.
Lastly, the prime minister asserted his view that
“the NHS is the best insurance system for the long
term,” with the founding principle that health care
should be available on the basis of need and not ability to pay. The importance of public funding is underlined by the need to pool risks as medical advances
offer increased potential to diagnose illnesses, the
increasing costs of some treatments, and the value of
these costs being shared to promote equity.
In setting out the direction of travel for the NHS,
the speech was much stronger on the government’s
priorities rather than how these will be achieved.
The emphasis on prevention is welcome, but will
more resources be shifted to make these aspirations
a reality?
Prevention has had numerous false dawns, extending back at least as far as 1976, and it is not clear
how the health reform programme in England will
be more successful than previous efforts in making
prevention “everybody’s business.”5
More detail is also needed on the plans to improve
care for people with chronic diseases. Personal health
budgets may empower some people, but they may
not be appropriate for people with complex comorbidity—the heaviest users of NHS services with the
greatest need for higher standards of care. Equally
challenging will be changing the culture of provision
53
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of health care to ensure that patients really are seen
as partners and are genuinely empowered to be active
participants in care.
These arguments indicate that there is a lacuna in
the prime minister’s announcements, namely the lack
of an explicit theory on how to change public services
like the NHS. Gordon Brown clearly does not share
Tony Blair’s enthusiasm for the use of markets (a word
notable by its absence from this speech), but he is yet
to reveal his alternative. This week’s statement is best
seen as the beginning of the process of identifying

a distinctively Brownite agenda for the NHS rather
than the final word.
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Three months after the interim report from Sir John
Tooke’s independent inquiry into Modernising Medical
Careers (MMC) in the United Kingdom1-3 comes the
final report.4-6
The interim report was well received—87% of
respondents to consultation either agreed or strongly
agreed with the original 45 recommendations. Some
of these have been slightly tweaked in the final report
and two new ones have been added—the creation of a
new oversight body for postgraduate medical education and training, and exploration of ways to legally
offset or compensate for the effects of the European
Working Time Directive.
For practising doctors the final report’s recommendations for the structure of postgraduate training will
matter most (see figure on bmj.com). Sir John recommends abandoning run through training for something
that seems familiar, beginning with a one year post
that resembles the pre-registration house officer of old,
followed by three years of core specialist training as a
registered doctor—a post that resembles the old senior
house officer grade.
The report argues for the uncoupling of current
foundation years 1 and 2 (FY1 and 2), which would
allow universities to guarantee a first medical job to
their graduates (currently, European Union medical graduates requiring provisional registration can
legitimately compete for FY1 positions). The current
FY2 year would be bundled in with current specialist training years 1 and 2 to make up three years of
core specialist training. The report rates the change as
“entirely consistent” with the principles of training that
has a broad based beginning and flexibility, which got
mysteriously subverted7 somewhere between the chief
medical officer’s 2002 consultation document Unfinished
Business: proposals for reform of the senior house officer grade
and the first MMC report a year later.
Entry to higher specialist training from core specialist
training would entail assessments administered several
times a year by national assessment centres, initially
introduced on a trial basis for highly competitive specialties. Shortlisting for structured interviews for higher

specialist training posts would take into account assessment scores, answers to specialty specific questions,
and structured CVs.
Successful completion of higher specialist training
would lead to a certificate of completion of training
“confirming readiness for independent practice in that
specialty at consultant level.” The interim report had
two discrete positions after completion of training—
“specialist” and “consultant”—separated by “optional
higher specialist exams”. This was understandably
interpreted as covert support for a subconsultant grade.
Despite some fancy footwork, the final report doesn’t
banish that suspicion entirely.
The length of training for general practice would
be extended to five years—three years of core training
plus two years as a general practitioner specialist registrar—bringing it in line with training in other developed
European countries.
The interim report laid many of the problems besetting MMC—including unclear lines of responsibility and
overemphasis on workforce imperatives—at the door of
the Department of Health. Sir John now redresses the
balance by proposing that the chief medical officer is
made the senior responsible officer for medical education and the medical profession’s reference point regarding postgraduate medical education and training.
The chief medical officer would also liaise closely
with a completely new body, NHS: Medical Education
England (NHS:MEE), the functions of which would
include defining the principles underpinning postgraduate medical education and training and holding the
ring fenced budget for these in England. The new body
is given a part to play in more than a third of the final
report’s recommendations.
The mismatch between numbers of applicants and
available training posts—one of the main causes of juniors’ pain in 2007—is beyond the report’s remit. Last
year there were 32 649 applicants for 23 247 specialist
training posts in the UK. F igure 4.17 of the interim
report shows that the oversupply of applicants (9402)
almost equals the number of applicants with highly
skilled migrant programme visas (10 014). This scheme,
BMJ | 12 January 2008 | Volume 336
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however, is the business of the Home Office and the
Treasury, and the Treasury is presumably happy to use
an oversupply of applicants to keep down the pressure
for salary increases. When the Department of Health
tried unilaterally to impose additional conditions to the
scheme, it was swatted down by the appeal court for
its pains.8 The best that the report can do is to call for
“a coherent model of medical workforce supply within
which apparently conflicting policies on self-sufficiency
and open-borders/overproduction should be publicly
disclosed and reconciled.”
What are the chances that all 47 of the final report’s
recommendations will be implemented? The executive summary concludes that strong agreement with
the interim report provided “a compelling mandate
for the implementation of the proposals.” But will the
government agree? Governments have long found the
best way to defuse a row is to appoint a suitably qualified member of the great and the good to conduct an
inquiry. Nothing need actually change once the hoohah
has blown over.
At the same time as Sir John was putting the finishing touches to his report, the House of Commons
select committee on health was taking evidence on
MMC—from many of the same people Sir John had
interviewed. Worryingly, it heard that the secretary of
state for health and chief medical officer had recently
defended the concept of run through training and were

going to retain it.9 It seems unlikely that the select committee’s final recommendations will be identical to Sir
John’s. And Lord Darzi’s broader review of the National
Health Service may also consider medical careers.
Before any other body’s recommendations about
postgraduate medical education and training are implemented, they must be shown to be superior to those
that have emerged from Sir John’s meticulous review
of the topic, conducted with an urgency that befits its
importance to doctors and patients alike.
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Preparing health professionals and the public for a flu
pandemic has been the subject of much research worldwide, and governments and public health departments
have published various recommendations over the past
five years.1-4 One aspect of the clinical management of
respiratory viruses—namely barrier methods to reduce
transmission—is assessed in the accompanying systematic review by Jefferson and colleagues.5 This review
found that handwashing and wearing masks, gloves,
and gowns were effective individually in preventing
the spread of severe
���������������������������������������
acute respiratory syndrome������
, and
even more effective when combined (odds ratio 0.09,
95% confidence interval 0.02 to 0.35, number needed
to treat (NNT)=3, 2.66 to 4.97). The incremental effect
of adding virucidals or antiseptics to normal handwashing to reduce respiratory disease was uncertain.
Because pandemic flu is such a potentially catastrophic event, governments worldwide should have
commissioned such a review many years ago and not
have left it to the academic community to take the
lead. The academic community needs to educate governments that expert advice is not necessarily the best
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advice. Guidelines should be based on rigorous systematic reviews and need to be continuously updated.
Government and international websites such as the
World Health Organization website on the status of
pandemic flu (www.who.int/csr/disease/avian_influenza/phase/en/index.html) are of some help in keeping health professionals up to date with the latest
information. However, regularly updated evidence
based guidelines containing levels of recommendation
and, where possible, measures of effectiveness such as
NNT would be very much more helpful to front line
clinicians. Guidelines also highlight where the strength
of the evidence is weak and more research is needed.
We have an annually updated guideline on the management of hypertension,6 and it reflects badly on the
consistency of knowledge translation that one is not
available for influenza.
The messages distributed by governments about
how to reduce the spread of respiratory viruses have
not been shown to be wrong, although some are not
supported by evidence. Jefferson and colleagues’
review will allow the effectiveness of the interventions
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and the strength of the evidence supporting them to
be much more explicit; for example, it will be possible to add numbers needed to treat for handwashing,
face masks, and gloves to advisory leaflets for health
professionals.
So how does the review help clinicians in primary
care? The benefit of washing hands between patients is
clear (NNT=4), as is wearing masks (NNT=6), wearing gloves (NNT=5), and wearing gowns (NNT=5). So
practices need to have a stock of gloves, simple masks
(not necessarily of the advanced N95 make), and gowns.
Applying all the recommendations described by various
government guidelines7—such as isolation, segregation,
transport, and identification of patients, creating emergency telephone lists of staff, and on-call cover when
staff are sick—may seem daunting to a small practice
or office. However, the one advantage with influenza,
compared with more sporadic epidemics such as pertussis, is that the practice plan can be tried, evaluated, and
modified each year.
Jefferson and colleagues point out that the quality of
the trials was highly variable. We do not have enough
evidence to be certain about many aspects of care for
patients with suspected influenza—for example, which
face mask is more cost effective within different healthcare settings. Although 336 trials on influenza have
been registered on the WHO international clinical trials

registry, only three trials are about reducing transmission using distancing (keeping a physical distance from
patients with suspected disease) or barrier methods. The
reasons for this include the lack of research capacity and
funding and an emphasis on drug based treatments.
Governments should continue to fund research to confirm the findings of this review and to investigate other
areas of uncertainty that it identifies in the management
of people with suspected influenza.
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On Wednesday 9 January 2008, the House of Commons
health select committee published the report of its
second inquiry into the National Institute for Health
and Clinical Excellence (NICE).1 The committee’s first
inquiry into NICE was published six years ago,2 just
three years after the institute’s launch. Much has happened since the initial inquiry. The institute is now
well established and is a core policy driver within the
National Health Service in England and Wales (its remit
does not cover Scotland), and we know much more
about how it operates. Moreover, the working environment of the institute has changed with, for instance, the
publication of the Cooksey report on funding for health
research in the United Kingdom,3 the introduction of
legislation making NICE technology appraisals essentially compulsory,4 the involvement of the courts in a
legal challenge to NICE,5 and most recently the Office
of Fair Trading’s critical review of how brand name
drugs are priced in the UK through the Pharmaceutical
Price Regulation Scheme (PPRS).6
All these and more have been embraced in this
new inquiry, for which members visited equivalent
bodies to NICE in Canada, France, and Scotland;
took oral evidence from 31 witnesses; and received
124 written submissions. The committee’s report
contains 32 recommendations, many of which are

far reaching and reflect the work of a particularly
effective inquisitorial team.
The report highlights certain disappointments—for
example, the failure of NICE to implement some of
the committee’s recommendations made in 2002, such
as making technology appraisals available at the time
of drug launches. And the report is critical of the way
ministers have tried to influence decision making by
NICE. At the same time the committee recognises
that NICE now plays a vital role in determining NHS
health policy and that this role is going to become
“more important and demanding.”
Four particularly notable themes emanate from the
recommendations, and these relate primarily to the
institute’s work on technology appraisals of drugs.
Firstly, the committee calls for greater clarity in NICE’s
decision making processes. The report recommends
more communication with stakeholders, a clarification
of the institute’s role as a rationing body, and a change
in terminology so that compulsory advice given in technology appraisals is referred to as a NICE directive,
leaving other advice from the institute to be referred
to as guidance or guidelines.
Secondly, the committee questions the threshold
used by NICE when determining whether or not a
new drug should be made available in the NHS. As a
BMJ | 12 January 2008 | Volume 336
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general rule, NICE recommends only new products
estimated to cost the NHS less than around £30 000
(€40 000; $59 000) per quality adjusted life year
(QALY) for use in the NHS. The committee learnt
that this amount was determined by NICE, does not
have any basis in hard science, has not changed since
NICE’s inception, is not related to the NHS budget, is
almost certainly higher than that which primary care
trusts use when they consider new drugs, and does not
take account of key costs such as those borne by carers and social services. The report recommends that a
body independent of NICE should be established to
review the threshold and set the levels and ranges that
the institute uses.
The committee also recommends that NICE
appraises all new drugs and that the results of appraisal
are available at the time of each drug’s launch. These
more rapid appraisals would, where appropriate, be
followed by more detailed single or multiple appraisals—as happen now—when more research became
available. Currently, NICE appraises only a proportion of drugs, and seems to concentrate on those that
are new, expensive, and used in acute medicine and
secondary care. Moreover, these appraisals are published months or years after a drug is marketed. The
current policy delays the introduction of effective new
drugs and diverts provision away from older, useful,
and possibly cheaper measures that have not been
appraised.
Lastly, the committee is concerned about the quality of the data available to NICE and how this quality
is assessed. The data used by NICE, which by and
large are generated by drug companies and relate to
published information, are often weak, inadequate, or
biased—and make reliable decision making difficult.
The committee wants trial data made available to

NICE that are more complete, more independent (of
the drug industry), more relevant to clinical practice,
and more amenable to the needs of economic evaluation. All the information available to the UK drug
licensing authority should also be available to NICE.
The Department of Health has three months to
respond to the report. All of the committee’s recommendations are challenging, but it is those relating to
the timing and breadth of the technology appraisals
that would have the widest implications; if adopted
they would inevitably reduce the amount we spend
on drugs and temper the influence the drug industry
has on clinical practice.7 Such changes would also have
an important bearing on the proposed reforms to the
Pharmaceutical Price Regulation Scheme, in which
drug prices would be negotiated at launch for each
drug by an independent commission using evidence
of the product’s perceived clinical value, including evidence from NICE.8
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Despite advances in our understanding of the epidemiology and distribution of deaths from pneumonia,1
more than 150 million cases of pneumonia still occur
annually, with almost 2.4 million deaths worldwide.
Pneumonia is perhaps the most frequent cause of
death in children under 5, including during the newborn period.2 Deaths from pneumonia in children
have increased in the wake of the HIV epidemic in
Africa. Most deaths occur early in the course of illness.
Because severe pneumonia is usually related to bacterial infection, treatment has largely focused on various
antibiotic strategies.
In the accompanying randomised controlled trial,
Asghar and colleagues compare the effectiveness of
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injectable ampicillin plus gentamicin or chloramphenicol in children aged 2-59 months with severe
pneumonia (defined by World Health Organization
criteria).3 The trial took place in inpatient wards in
tertiary care hospitals in Bangladesh, Ecuador, India,
Mexico, Pakistan, Yemen, and Zambia. Significantly
more children failed treatment with chloramphenicol
at five days (16% v 11%, relative risk 1.43, 95% confidence interval 1.03 to 1.97).
The study is one of a series of recent studies aiming to improve the treatment of childhood pneumonia in various settings.4 5 These findings confirm
that the increasing resistance of common respiratory
bacterial pathogens like Streptoccoccus pneumoniae and
57
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Haemophilus influenzae to first line antibiotics, such as
co-trimoxazole and chloramphenicol, means that recommendations for treating suspected and confirmed
pneumonia need to be changed.
Several limitations must be kept in mind before generalising these findings to the treatment of all children
with very severe pneumonia. The study was restricted
to children older than 2 months and might not apply
to a large proportion of newborns and young infants
who may have a different cause of pneumonia. Children with empyema or overt pneumatoceles (suggestive of possible Staphylococcus aureus infection) were
excluded. Similarly, children with wheezing were not
included, which potentially limits the applicability of
these findings to children with secondary infections
related to infection with respiratory syncytial virus or
other viruses.6
Given that most deaths from pneumonia occur early
in the course of the illness, health workers using the
integrated management for childhood illness guidelines
need to have clear algorithms for triage, stabilisation
of children, and initiation of antibiotics. The antibiotic regimens for treating non-severe, severe, and very
severe pneumonia should therefore form a continuum
that is easy for health systems to implement and monitor on a large scale.
Despite the above limitations, given the increasing rates of drug resistance in common bacteria
that cause pneumonia—such as Streptococcus pneumoniae and Haemophilus influenzae7—the current study
supports the switch to more effective antibiotics.
However, the combination of ampicillin and
gentamicin may not be the best choice for developing countries. The need for multiple doses when
using this combination may cause problems and
lead to reduced adherence. The combination has
limited coverage against Staphylococcus aureus, and
there are legitimate concerns about the spectrum of
pathogens that it covers. The spectrum of respiratory infections may have changed in regions where
Haemophilus influenzae type B vaccine or the new
pneumococcal conjugate vaccines have been introduced to include infections with non-vaccine strains
as well as Gram negative pathogens.
The growing HIV epidemic in Africa has also
altered the epidemiology and spectrum of lower respiratory tract infections in infected children. Cytomegalovirus, Pneumocystis jiroveci, and multi-drug resistant
non-typhoidal Salmonella are now well known to cause
pneumonia in children in Africa.8 Acute pulmonary
tuberculosis may also present with features suggestive
of severe pneumonia and must be kept in mind in
susceptible populations.
It may be better to use once daily injectable cephalosporins such as ceftriaxone or fluoroquinolones
for treating children with very severe pneumonia
who require hospital admission or observed ambulatory therapy.9 However, the blanket use of second line antimicrobial agents in pneumonia makes
the emergence of future resistance more likely, so
tighter objective criteria are needed for diagnosing
58

severe or very severe pneumonia. Many viral lower
respiratory tract infections present with tachypnoea
and chest recessions, and it may be difficult to distinguish them from bacterial infections on clinical criteria
alone.10 Although recent studies do not indicate a
good correlation between radiological results and
clinically defined pneumonia,11 the use of portable
pulse oximetry may help triage children for hospital
admission and additional treatment, such as oxygen
and injectable antibiotics.12 This approach needs to
be validated in studies of appropriate diagnostic tools,
including newer molecular methods that enable viral
and bacterial infections (or combinations of the two)
to be identified.
In the long term, the most cost effective way to
reduce childhood mortality from pneumonia is to
scale up effective evidence based preventive strategies.
These strategies include promoting effective childhood
immunisations (especially against measles, invasive
Haemophilus influenzae type B, pneumococcal infections, and possibly influenza), improving environmental conditions through clean water and sanitation, and
reducing indoor air pollution. In addition, improving
nutrition at a population level may reduce intrauterine
growth retardation and deficiencies in micronutrients,
such as zinc and vitamin A. The challenge is to make
this happen on a large scale.
1

Rudan I, Tomaskovic L, Boschi-Pinto C, Campbell H; WHO Child Health
Epidemiology Reference Group. Global estimate of the incidence of
clinical pneumonia among children under five years of age. Bull World
Health Organ 2004;82:895-903.
2 Wardlaw T, Salama P, Johansson EW, Mason E. Pneumonia: the
leading killer of children. Lancet 2006;368:1048-50.
3 Asghar R, Banajeh S, ���������������������������������������������������
Egas J, �������������������������������������������
Hibberd P, Iqbal I, Katep-Bwalya M, et al.
Chloramphenicol versus ampicillin plus gentamicin for community
acquired very severe pneumonia among children aged 2-59 months
in low resource settings: multicentre randomised controlled trial
(SPEAR study). BMJ 2008 doi: 10.1136/bmj.39421.435949.BE.
4 Atkinson M, Lakhanpaul M, Smyth A, Vyas H, Weston V, Sithole J, et
al. Comparison of oral amoxicillin and intravenous benzyl penicillin
for community acquired pneumonia in children (PIVOT trial): a
multicentre pragmatic randomised controlled equivalence trial.
Thorax 2007;62:1102-6.
5 Addo-Yobo E, Chisaka N, Hassan M, Hibberd P, Lozano JM, Jeena P, et
al. Oral amoxicillin versus injectable penicillin for severe pneumonia
in children aged 3 to 59 months: a randomised multicentre
equivalency study. Lancet 2004;364:1141-8.
6 Klein MI, Coviello S, Bauer G, Benitez A, Serra ME, Schiatti MP, et al.
The impact of infection with human metapneumovirus and other
respiratory viruses in young infants and children at high risk for severe
pulmonary disease. J Infect Dis 2006;193:1544-51.
7 Cardoso MR, Nascimento-Carvalho CM, Ferrero F, Berezin EN,
Ruvinsky R, Camargos PA, et al. ����������������������������������
Penicillin resistant pneumococcus
and risk of treatment failure in pneumonia. Arch Dis Child 2007
Published online 11 September 2007.
8 Graham SM. Impact of HIV on childhood respiratory illness:
differences between developing and developed countries. Pediatr
Pulmonol 2003;36:462-8.
9 Bradley JS, Arguedas A, Blumer JL, Sáez-Llorens X, Melkote R, Noel GJ.
Comparative study of levofloxacin in the treatment of children with
community-acquired pneumonia. Pediatr Infect Dis J 2007;26:86878.
10 Bhutta ZA. Dealing with childhood pneumonia in developing
countries: how can we make a difference? Arch Dis Child
2007;92:286-8.
11 Hazir T, Nisar YB, Qazi SA, Khan SF, Raza M, Zameer S, et al. Chest
radiography in children aged 2-59 months diagnosed with non-severe
pneumonia as defined by World Health Organization: descriptive
multicentre study in Pakistan. BMJ 2006;333:629.
12 Fu LY, Ruthazer R, Wilson I, Patel A, Fox LM, Tuan TA, et al. Brief
hospitalization and pulse oximetry for predicting amoxicillin
treatment failure in children with severe pneumonia. Pediatrics
2006;118:e1822-30.
BMJ | 12 January 2008 | Volume 336

